(Q37823558)

23 August 2017

1 reference

title

Clinical management of treatment-experienced, HIV/AIDS patients in the combination antiretroviral therapy era. (English)

1 reference

23 August 2017

0 references

anti-retroviral agent

0 references

Mark A Boyd

1

0 references

author name string

Andrew M Hill

series ordinal

2

1 reference

23 August 2017

publication date

1 January 2010

1 reference

23 August 2017

1 reference

23 August 2017

volume

28 Suppl 1

1 reference

23 August 2017

page(s)

17-34

1 reference

https://scigraph.springernature.com/pub.10.2165/11587420-000000000-00000

23 August 2017

exact match

0 references

cites work

The AIDS epidemic--considerations for the 21st century

1 reference

https://api.crossref.org/works/10.2165%2F11587420-000000000-00000

Twenty years of therapy for HIV-1 infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587420-000000000-00000

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587420-000000000-00000

The President's Emergency Plan for AIDS Relief in Africa: an evaluation of outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587420-000000000-00000

Decline in the AIDS and death rates in the EuroSIDA study: an observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587420-000000000-00000

The changing face of the HIV epidemic in western Europe: what are the implications for public health policies?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587420-000000000-00000

The survival benefits of AIDS treatment in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587420-000000000-00000

Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587420-000000000-00000

Adherence to HAART among patients with HIV: breakthroughs and barriers

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587420-000000000-00000

A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587420-000000000-00000

Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587420-000000000-00000

Intentional nonadherence due to adverse symptoms associated with antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587420-000000000-00000

Combination antiretroviral therapy and the risk of myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587420-000000000-00000

Cardiovascular risk and body-fat abnormalities in HIV-infected adults

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587420-000000000-00000

Drug interactions in the management of HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587420-000000000-00000

Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587420-000000000-00000

An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587420-000000000-00000

Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587420-000000000-00000

Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587420-000000000-00000

Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587420-000000000-00000

Time to virological failure of 3 classes of antiretrovirals after initiation of highly active antiretroviral therapy: results from the EuroSIDA study group

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587420-000000000-00000

Treatment exhaustion of highly active antiretroviral therapy (HAART) among individuals infected with HIV in the United Kingdom: multicentre cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587420-000000000-00000

Clinical and immunogenetic correlates of abacavir hypersensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587420-000000000-00000

Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587420-000000000-00000

The use of and response to second-line protease inhibitor regimens: results from the EuroSIDA study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587420-000000000-00000

Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587420-000000000-00000

Correlation between intracellular pharmacological activation of nucleoside analogues and HIV suppression in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587420-000000000-00000

Current status of the non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587420-000000000-00000

Antiretrovirals, part 1: overview, history, and focus on protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587420-000000000-00000

Enfuvirtide: a review of its use in the management of HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587420-000000000-00000

The entry of entry inhibitors: a fusion of science and medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587420-000000000-00000

Maraviroc for previously treated patients with R5 HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587420-000000000-00000

Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587420-000000000-00000

Raltegravir with optimized background therapy for resistant HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587420-000000000-00000

Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587420-000000000-00000

CD4+ count-guided interruption of antiretroviral treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587420-000000000-00000

The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587420-000000000-00000

Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587420-000000000-00000

Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587420-000000000-00000

Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587420-000000000-00000

Quality of life, emotional status, and adherence of HIV-1-infected patients treated with efavirenz versus protease inhibitor-containing regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587420-000000000-00000

Long-term assessment of neuropsychiatric adverse reactions associated with efavirenz

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587420-000000000-00000

Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587420-000000000-00000

Management of protease inhibitor-associated diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587420-000000000-00000

Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587420-000000000-00000

The management of HIV-1 protease inhibitor pharmacokinetic interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587420-000000000-00000

A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587420-000000000-00000

Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587420-000000000-00000

A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587420-000000000-00000

Prevalence and predictors of antiretroviral drug resistance in newly diagnosed HIV-1 infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587420-000000000-00000

Prevalence and clinical significance of HIV drug resistance mutations by ultra-deep sequencing in antiretroviral-naïve subjects in the CASTLE study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587420-000000000-00000

Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587420-000000000-00000

Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587420-000000000-00000

Emergence of resistance to protease inhibitor amprenavir in human immunodeficiency virus type 1-infected patients: selection of four alternative viral protease genotypes and influence of viral susceptibility to coadministered reverse transcriptase n

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587420-000000000-00000

Drug resistance in patients experiencing early virological failure under a triple combination including indinavir

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587420-000000000-00000

Prevalence and predictive value of intermittent viremia with combination hiv therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587420-000000000-00000

Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587420-000000000-00000

Class-sparing regimens for initial treatment of HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587420-000000000-00000

Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587420-000000000-00000

Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587420-000000000-00000

The role of abacavir (ABC, 1592) in antiretroviral therapy-experienced patients: results from a randomized, double-blind, trial. CNA3002 European Study Team

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587420-000000000-00000

Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587420-000000000-00000

Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587420-000000000-00000

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587420-000000000-00000

Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587420-000000000-00000

In-vitro tipranavir susceptibility of HIV-1 isolates with reduced susceptibility to other protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587420-000000000-00000

TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587420-000000000-00000

Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug r

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587420-000000000-00000

Atazanavir enhances saquinavir hard-gel concentrations in a ritonavir-boosted once-daily regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587420-000000000-00000

Saquinavir drug exposure is not impaired by the boosted double protease inhibitor combination of lopinavir/ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587420-000000000-00000

Virologic efficacy of boosted double versus boosted single protease inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587420-000000000-00000

Pharmacokinetics and short-term efficacy of a double-boosted protease inhibitor regimen in treatment-naive HIV-1-infected adults

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587420-000000000-00000

Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587420-000000000-00000

Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587420-000000000-00000

Multiple drug rescue therapy for HIV-infected individuals with prior virologic failure to multiple regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587420-000000000-00000

Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587420-000000000-00000

Re-occurrence of HIV-1 drug mutations after treatment re-initiation following interruption in patients with multiple treatment failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587420-000000000-00000

Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3',3'-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587420-000000000-00000

British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587420-000000000-00000

Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587420-000000000-00000

A randomized trial to evaluate lopinavir/ritonavir versus saquinavir/ritonavir in HIV-1-infected patients: the MaxCmin2 trial.

21 January 2018

1 reference

12 December 2020

Baseline resistance and virological outcome in patients with virological failure who start a regimen containing abacavir: EuroSIDA study

1 reference

12 December 2020

Protease-inhibitor boosting in the treatment-experienced patient.

1 reference

12 December 2020

Triple-class antiretroviral drug resistance: risk and predictors among HIV-1-infected patients

1 reference

12 December 2020

Immune Reconstitution Syndrome in HIV: Validating a Case Definition and Identifying Clinical Predictors in Persons Initiating Antiretroviral Therapy

1 reference

12 December 2020

Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice

1 reference

12 December 2020

Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Department of Health and Human Services and the Henry J. Kaiser Family Foundation

1 reference

12 December 2020

Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial

1 reference

12 December 2020

Risk of AIDS and death at given HIV-RNA and CD4 cell count, in relation to specific antiretroviral drugs in the regimen

1 reference

12 December 2020

Immunopathogenesis of human immunodeficiency virus.

1 reference

12 December 2020

Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1

1 reference

12 December 2020

HIV drug susceptibility and treatment response to mega-HAART regimen in patients from the Frankfurt HIV cohort

1 reference

12 December 2020

Correlates and predictors of adherence to highly active antiretroviral therapy: overview of published literature

1 reference

12 December 2020

Update of the drug resistance mutations in HIV-1: Fall 2005.

1 reference

12 December 2020

Antiviral efficacy of abacavir in antiretroviral therapy-experienced adults harbouring HIV-1 with specific patterns of resistance to nucleoside reverse transcriptase inhibitors

1 reference

12 December 2020

Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial

1 reference

12 December 2020

Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails

1 reference

12 December 2020

1 reference

12 December 2020

The long-term consequences of antiretroviral therapy: a review

1 reference

12 December 2020

Improved survival in HIV-infected persons: consequences and perspectives

1 reference

12 December 2020

New HIV drug classes on the horizon

1 reference

12 December 2020

Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia

1 reference

12 December 2020

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial.

1 reference

12 December 2020

10.2165/11587420-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

23 August 2017

1026075123

0 references

1 reference